P450 Enzymes

[1]  F. Clerc,et al.  Identification of the main epitope on human cytochrome P450 IID6 recognized by anti-liver kidney microsome antibody. , 1991, Journal of Autoimmunity.

[2]  E. Skjelbo,et al.  Fluoxetine and norfluoxetine are potent inhibitors of P450IID6--the source of the sparteine/debrisoquine oxidation polymorphism. , 1991, British journal of clinical pharmacology.

[3]  U. Meyer,et al.  Role of P450IID6, the target of the sparteine‐debrisoquin oxidation polymorphism, in the metabolism of imipramine , 1991, Clinical pharmacology and therapeutics.

[4]  R. Tyndale,et al.  Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). , 1991, British journal of clinical pharmacology.

[5]  M. J. Coon,et al.  The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. , 1991, DNA and cell biology.

[6]  M. Eichelbaum,et al.  Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. , 1991, American journal of human genetics.

[7]  J. Miners,et al.  Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. , 1991, Biochemical and biophysical research communications.

[8]  C. Bahr,et al.  Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype , 1991, Clinical pharmacology and therapeutics.

[9]  F. Guengerich,et al.  Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. , 1991, The Journal of pharmacology and experimental therapeutics.

[10]  A. Kolyada.  Sequence of a human liver cytochrome P-450 cDNA clone. , 1990, Nucleic acids research.

[11]  C. Bonfils,et al.  Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[12]  A. Breckenridge,et al.  In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme. , 1990, British journal of clinical pharmacology.

[13]  S. Wrighton,et al.  Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). , 1990, Molecular pharmacology.

[14]  F. Guengerich.  Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. , 1990, Chemical research in toxicology.

[15]  P. Beaune,et al.  Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis. , 1990, The Journal of clinical investigation.

[16]  M. Rogawski,et al.  Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. , 1990, Pharmacological reviews.

[17]  M. A. Chambers,et al.  Inhibition and induction of theophylline metabolism by 8-methoxypsoralen. In vivo study in rats and humans. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[18]  W. Haefeli,et al.  Potent Inhibition of Cytochrome P450IID6 (Debrisoquin 4‐Hydroxylase) by Flecainide In Vitro and In Vivo , 1990, Journal of cardiovascular pharmacology.

[19]  J. S. Miles,et al.  Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. , 1990, The Biochemical journal.

[20]  H. T. Karnes,et al.  In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes , 1990, Antimicrobial Agents and Chemotherapy.

[21]  F. Gonzalez,et al.  Mutagenic activation of 2-amino-3-methylimidazo[4,5-f]quinoline by complementary DNA-expressed human liver P-450. , 1990, Cancer research.

[22]  D. Abernethy,et al.  Metabolite inhibition of parent drug biotransformation. Studies of diltiazem. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[23]  F. Gonzalez,et al.  The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. , 1990, Biochemistry.

[24]  U. Meyer,et al.  Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: Relationship to the presence of immunoidentified cytochrome P‐450IID1 , 1990, Clinical pharmacology and therapeutics.

[25]  M. Relling,et al.  Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. , 1990, The Journal of pharmacology and experimental therapeutics.

[26]  R. Janknegt.  Drug interactions with quinolones. , 1990, The Journal of antimicrobial chemotherapy.

[27]  U. Meyer,et al.  Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4 , 1989, Clinical pharmacology and therapeutics.

[28]  J. Schuetz,et al.  Characterization of a cDNA encoding a new member of the glucocorticoid-responsive cytochromes P450 in human liver. , 1989, Archives of biochemistry and biophysics.

[29]  T. Aoyama,et al.  cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver. , 1989, Biochemistry.

[30]  D. Nebert,et al.  Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. , 1989, Molecular endocrinology.

[31]  H. Kuhl,et al.  Interaction with the pharmacokinetics of ethinylestradiol and progestogens contained in oral contraceptives. , 1989, Contraception.

[32]  M. Goldberg,et al.  Inhibition of alfentanil metabolism by erythromycin , 1989, Clinical pharmacology and therapeutics.

[33]  T. Kamataki,et al.  Isolation of a new human fetal liver cytochrome P450 cDNA clone: evidence for expression of a limited number of forms of cytochrome P450 in human fetal livers. , 1989, Archives of biochemistry and biophysics.

[34]  T. Kronbach,et al.  Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. , 1989, Molecular pharmacology.

[35]  R. Kato,et al.  cDNA and deduced amino acid sequences of human P450 IIA3 (CYP2A3). , 1989, Nucleic acids research.

[36]  T. Aoyama,et al.  Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. , 1989, The Journal of biological chemistry.

[37]  C. Lieber,et al.  Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. , 1989, Archives of biochemistry and biophysics.

[38]  L. Bertilsson,et al.  Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S‐mephenytoin, but not debrisoquin, hydroxylation phenotype , 1989, Clinical pharmacology and therapeutics.

[39]  G. Farrell,et al.  Downregulation of the male-specific hepatic microsomal steroid 16 alpha-hydroxylase, cytochrome P-450UT-A, in rats with portal bypass. Relevance to estradiol accumulation and impaired drug metabolism in hepatic cirrhosis. , 1989, The Journal of clinical investigation.

[40]  G. Farrell,et al.  Effect of liver regeneration on hepatic cytochrome P450 isozymes and serum sex steroids in the male rat. , 1989, Gastroenterology.

[41]  P. Watkins,et al.  Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. , 1989, The Journal of clinical investigation.

[42]  T. Kamataki,et al.  Molecular cloning and sequence analysis of cDNA containing the entire coding region for human fetal liver cytochrome P-450. , 1989, Journal of biochemistry.

[43]  P. Srivastava,et al.  Characterization of mRNA species related to human liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity. , 1989, The Journal of biological chemistry.

[44]  P. Dayer,et al.  Dextromethorphan O‐demethylation in liver microsomes as a prototype reaction to monitor cytochrome P‐450 db1 activity , 1989, Clinical pharmacology and therapeutics.

[45]  T. Kronbach,et al.  In vitro characterization of the human cytochrome P‐450 involved in polymorphic oxidation of propafenone , 1989, Clinical pharmacology and therapeutics.

[46]  R. Branch,et al.  Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities , 1989, Clinical pharmacology and therapeutics.

[47]  S. Povey,et al.  Cloning, experession and chromosomal localization of a member of the human cytochrome P450IIC gene sub‐family , 1989, Annals of human genetics.

[48]  M. Correia,et al.  Secobarbital-mediated inactivation of rat liver cytochrome P-450b: a mechanistic reappraisal. , 1989, Molecular pharmacology.

[49]  M. Relling,et al.  Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephenytoin hydroxylase, in human liver microsomes. , 1989, Cancer research.

[50]  H. Hauri,et al.  Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[51]  U. Meyer,et al.  Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism. , 1988, Biochemical pharmacology.

[52]  P. Srivastava,et al.  Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4'-hydroxylase. , 1988, Biochemistry.

[53]  J. S. Miles,et al.  A novel human cytochrome P450 gene (P450IIB): chromosomal localization and evidence for alternative splicing , 1988, Nucleic Acids Res..

[54]  F. Guengerich,et al.  Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation. , 1988, The Journal of pharmacology and experimental therapeutics.

[55]  T. Leemann,et al.  Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). , 1988, Biochemical and biophysical research communications.

[56]  O. Mcbride,et al.  Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. , 1988, DNA.

[57]  H. Kleinman,et al.  Regulation of gene expression in adult rat hepatocytes cultured on a basement membrane matrix , 1988, Journal of cellular physiology.

[58]  D. Nebert,et al.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism , 1988, Nature.

[59]  D. Nebert,et al.  Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. , 1988, Genomics.

[60]  M. Murray,et al.  Comparative effects of antithrombitic and antimycotic N-substituted imidazoles on rat hepatic microsomal steroid and xenobiotic hydroxylases in vitro. , 1988, Biochemical pharmacology.

[61]  F. Gonzalez,et al.  cDNA and amino acid sequences of two members of the human P450IIC gene subfamily. , 1987, Nucleic acids research.

[62]  P. Cheney,et al.  Methoxsalen is a potent inhibitor of the metabolism of caffeine in humans , 1987, Clinical pharmacology and therapeutics.

[63]  M. Ene,et al.  Pharmacokinetics of Nifedipine After Oral Administration in Chronic Liver Disease , 1987, Journal of clinical pharmacology.

[64]  R. Tukey,et al.  Characterization of multiple human cytochrome P-450 1 cDNAs. The chromosomal localization of the gene and evidence for alternate RNA splicing. , 1987, The Journal of biological chemistry.

[65]  F. Shepherd,et al.  Medical management of malignant pericardial effusion by tetracycline sclerosis. , 1987, The American journal of cardiology.

[66]  D. Abernethy,et al.  N-monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives. , 1987, British journal of clinical pharmacology.

[67]  G. Labbe,et al.  Effects of methoxsalen on the metabolism of acetaminophen in humans. , 1987, Biochemical pharmacology.

[68]  G. Farrell,et al.  Impaired androgen 16 alpha-hydroxylation in hepatic microsomes from carbon tetrachloride-cirrhotic male rats. , 1987, Gastroenterology.

[69]  F. Guengerich,et al.  Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. , 1987, The Journal of pharmacology and experimental therapeutics.

[70]  D. Pessayre,et al.  Inactivation of human liver cytochrome P-450 by the drug methoxsalen and other psoralen derivatives. , 1987, Biochemical pharmacology.

[71]  F. Guengerich,et al.  Cloning and sequence determination of a complementary DNA related to human liver microsomal cytochrome P-450 S-mephenytoin 4-hydroxylase. , 1987, Biochemistry.

[72]  P. Beaune,et al.  Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[73]  P. Watkins,et al.  Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[74]  G. Tucker,et al.  Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.

[75]  W. Kalow.  The genetic defect of mephenytoin hydroxylation. , 1986, Xenobiotica; the fate of foreign compounds in biological systems.

[76]  G. Tucker,et al.  Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies. , 1985, British journal of clinical pharmacology.

[77]  R. Branch,et al.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.

[78]  J. Halpert,et al.  Isozyme selectivity of the inhibition of rat liver cytochromes P-450 by chloramphenicol in vivo. , 1985, Molecular pharmacology.

[79]  G. Danan,et al.  Drug‐induced hepatitis associated with anticytoplasmic organelle autoantibodies , 1985, Hepatology.

[80]  R. Branch,et al.  Phenotypic differences in mephenytoin pharmacokinetics in normal subjects. , 1985, The Journal of pharmacology and experimental therapeutics.

[81]  D. Hassell,et al.  Suspected interaction: warfarin and erythromycin. , 1985, Southern medical journal.

[82]  W. Kalow,et al.  In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. , 1985, Drug metabolism and disposition: the biological fate of chemicals.

[83]  N. Gerber,et al.  Drug interactions with cimetidine: an update. , 1985, Pharmacology & therapeutics.

[84]  K. Midha,et al.  METHOXYPHENAMINE AND DEXTROMETHORPHAN AS SAFE PROBES FOR DEBRISOQUINE HYDROXYLATION POLYMORPHISM , 1984, The Lancet.

[85]  M. Danhof,et al.  Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. , 1984, Biochemical pharmacology.

[86]  B. Mellström,et al.  Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes , 1984, Clinical pharmacology and therapeutics.

[87]  G. Alván,et al.  Relationship of N‐demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism , 1984, Clinical pharmacology and therapeutics.

[88]  D. Roden,et al.  Influence of genetic polymorphism on the metabolism and disposition of encainide in man. , 1984, The Journal of pharmacology and experimental therapeutics.

[89]  D. Evans,et al.  Polymorphic hydroxylation of perhexiline maleate in man. , 1984, Journal of medical genetics.

[90]  J. Idle,et al.  The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition. , 1983, British journal of clinical pharmacology.

[91]  D. Feldman,et al.  Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. , 1983, The Journal of clinical investigation.

[92]  J. Idle,et al.  Genetic polymorphism of phenformin 4‐hydroxylation , 1982, Clinical pharmacology and therapeutics.

[93]  J. Idle,et al.  BETA BLOCKERS AND DRUG OXIDATION STATUS , 1982, The Lancet.

[94]  L. Balant,et al.  BETA-BLOCKERS AND DRUG OXIDATION STATUS , 1982, The Lancet.

[95]  L. Bertilsson,et al.  Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities , 1982, Clinical pharmacology and therapeutics.

[96]  R. Struck,et al.  Studies on the mechanism of denaturation of cytochrome P-450 by cyclophosphamide and its metabolites. , 1981, The Journal of biological chemistry.

[97]  L. Bertilsson,et al.  E‐ and Z‐10‐hydroxylation of nortriptyline: Relationship to polymorphic debrisoquine hydroxylation , 1981, Clinical pharmacology and therapeutics.

[98]  F. Bochner,et al.  Cimetidine interaction with phenytoin. , 1981, British medical journal.

[99]  J. Idle,et al.  Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation , 1981, Clinical pharmacology and therapeutics.

[100]  A. Heagerty,et al.  CIMETIDINE AND BIOAVAILABILITY OF PROPRANOLOL , 1981, The Lancet.

[101]  U. Klotz,et al.  Delayed clearance of diazepam due to cimetidine. , 1980, The New England journal of medicine.

[102]  J. Idle,et al.  Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine. , 1979, Xenobiotica; the fate of foreign compounds in biological systems.

[103]  J. Idle,et al.  Polymorphism of carbon oxidation of drugs and clinical implications. , 1978, British medical journal.

[104]  D. Hudgel,et al.  Inhibition of theophylline clearance by troleandomycin. , 1977, The Journal of allergy and clinical immunology.

[105]  S. Schenker,et al.  Drug disposition and liver disease. , 1975, Drug metabolism reviews.

[106]  H. Bolt,et al.  Studies on the metabolism of ethynylestradiol in vitro and in vivo: the significance of 2-hydroxylation and the formation of polar products. , 1973, Xenobiotica; the fate of foreign compounds in biological systems.

[107]  C. F. Wilkinson,et al.  Imidazole derivatives--a new class of microsomal enzyme inhibitors. , 1972, Biochemical pharmacology.